The Motley FoolMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug MarketYesterdayAdria CiminoBy Adria Ciminomore_vert
CNNWeight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says8 days agoJen ChristensenBy Jen Christensenmore_vert
Investors | Eli Lilly and CompanyTirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity | Eli Lilly and Company8 days agomore_vert
The New York TimesSleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports8 days agoGina KolataBy Gina Kolatamore_vert
Medical News TodaySleep apnea: Zepbound, Mounjaro improves symptoms in clinical trial2 days agoCorrie PelcBy Corrie Pelcmore_vert
ReutersEli Lilly to acquire manufacturing facility from Nexus Pharma3 days agoChristy Santhosh & Muhammad Tasim ZahidBy Christy Santhosh & Muhammad Tasim Zahidmore_vert
Investors | Eli Lilly and CompanyLilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals | Eli Lilly and Company3 days agomore_vert
Yahoo FinanceLilly to buy injectable drug plant in manufacturing ramp-up3 days agoDelilah AlvaradoBy Delilah Alvaradomore_vert
WISN MilwaukeeWisconsin family-owned manufacturer acquired by pharma giant Eli Lily2 days agoMariana La RocheBy Mariana La Rochemore_vert
TipRanksEli Lilly (NYSE:LLY) Notches Up on New Manufacturing Plans - TipRanks.com3 days agoSteve AndersonBy Steve Andersonmore_vert
CNBCMost doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says8 days agoAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
diaTribe FoundationShortages for Mounjaro, Zepbound, and Others to Last Through Summer3 days agoApril HopcroftBy April Hopcroftmore_vert
KCBDShortage of diabetes and weight loss drugs causing challenges for patients, pharmacies and doctors2 days agoSydney LowtherBy Sydney Lowthermore_vert
KABC-TVDoctors speak out amid weight loss drug shortages | What it means for patients2 days agoJanai NormanBy Janai Normanmore_vert
Yahoo FinanceInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to KnowYesterdaymore_vert
Yahoo FinanceEli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth2 days agomore_vert
MorningstarGoing Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?2 days agoDamien ConoverBy Damien Conovermore_vert
Yahoo FinanceEli Lilly and Company (LLY) Rose due to Robust Q4 Sales2 days agoSoumya EswaranBy Soumya Eswaranmore_vert
Yahoo FinanceShould Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?23 hours agoKinjel ShahBy Kinjel Shahmore_vert
Indianapolis Business JournalLilly's $3.7B manufacturing campus in Boone County starting to take shape – Indianapolis Business Journal2 days agoJohn RussellBy John Russellmore_vert
Reuters.comEli Lilly's nationwide insulin pricing settlement called off10 days agoBrendan PiersonBy Brendan Piersonmore_vert
Yahoo FinanceMetsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo7 days agoBen FidlerBy Ben Fidlermore_vert
Seeking AlphaEli Lilly And The Alzheimer's Dilemma (NYSE:LLY)3 days agoLane SimonianBy Lane Simonianmore_vert
Reuters.comLilly's weight-loss drug Zepbound to face supply crunch through April-end, US FDA says22 days agoSriparna Roy, Christy Santhosh & Shilpi MajumdarBy Sriparna Roy, Christy Santhosh & Shilpi Majumdarmore_vert
New York Post Desperate users of Ozempic rival Zepbound drive five hours to get weight-loss meds because of shortages17 days agoAriel ZilberBy Ariel Zilbermore_vert
Yahoo FinanceWeight-loss drug shortage result of 'unprecedented demand'17 days agoJulie HymanBy Julie Hymanmore_vert
PEOPLEWeight Loss Drugs Zepbound and Mounjaro Are in Shortage Due to 'Demand Increase,' FDA Says20 days agoVanessa EtienneBy Vanessa Etiennemore_vert
The Motley FoolEli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock19 days agomore_vert
FortuneEli Lilly warns weight-loss drug Zepbound may be hard to getMar 30Ike Swetlitz & Madison MullerBy Ike Swetlitz & Madison Mullermore_vert
ForbesHere's Why Ozempic And Mounjaro Rivals Won't Topple Drugmakers Novo Nordisk And Eli Lilly Anytime SoonMar 27Robert HartBy Robert Hartmore_vert
FiercePharma'Unprecedented' demand for Eli Lilly's Zepbound sparks US supply constraintsMar 29Zoey BeckerBy Zoey Beckermore_vert
CNNEli Lilly warns of temporary short supply of two insulin productsMar 22Meg TirrellBy Meg Tirrellmore_vert
Reuters.comLilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first timeMar 15Patrick WingroveBy Patrick Wingrovemore_vert
Medical News TodayAlzheimer's: FDA delays approval for Eli Lilly's donanemabMar 13Finn Maguire CohenBy Finn Maguire Cohenmore_vert
TipRanksLLY vs. JNJ: Which Big Pharma Stock Is Better? - TipRanks.com9 hours agoMichelle Deboer-jonesBy Michelle Deboer-jonesmore_vert
FiercePharmaIn banner year, Lilly rewards CEO David Ricks with 24% boost in total pay to $26.6MMar 25Kevin DunleavyBy Kevin Dunleavymore_vert
CNBCEli Lilly taps Amazon Pharmacy to help deliver weight loss drug Zepbound, other medicines to patientsMar 13Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
WPTV News Channel 5 West PalmBoca Raton diabetes patient impacted by Eli Lilly insulin shortageMar 29Jessica BrunoBy Jessica Brunomore_vert
Pharmaceutical TechnologyEli Lilly-backed Zephyr AI secures $111m for precision medicine techMar 14Robert BarrieBy Robert Barriemore_vert
CBS NewsEli Lilly's new ad says weight-loss drugs shouldn't be used out of "vanity"Mar 8Megan CerulloBy Megan Cerullomore_vert
USA TODAYMounjaro shortage update: Is it on backorder and when will it be back in stock?Mar 5Mary Walrath-holdridgeBy Mary Walrath-holdridgemore_vert
WYPRBaltimore files suit against Eli Lilly and others for price gougingMar 20Scott MaucioneBy Scott Maucionemore_vert
Financial TimesEli Lilly races to boost capacity as it rolls out rival to Novo Nordisk weight-loss drugMar 4more_vert
Business WireRedwire Partners with Eli Lilly and Company on Second Spaceflight Mission to Conduct Additional Research on Chronic Diseases Following Successful ResultsMar 12more_vert
CNBCEli Lilly says weight loss drug shows promise as treatment for fatty liver diseaseFeb 6Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
Reuters.comLilly rides wave of weight-loss drug demand, working to expand capacityFeb 6Patrick Wingrove & Bhanvi SatijaBy Patrick Wingrove & Bhanvi Satijamore_vert
Financial TimesEli Lilly calls for scrutiny of rival Novo Nordisk's deal to expand production of weight-loss drugFeb 6more_vert
Bloomberg(LLY) Lilly Closer to Joining Magnificent Seven in $1 Trillion Market Cap ClubFeb 16Lisa Pham & Joel LeonBy Lisa Pham & Joel Leonmore_vert
Indianapolis Business JournalLilly employees have seen big wins as stock price surges 500% since 2019 – Indianapolis Business JournalMar 1John RussellBy John Russellmore_vert
AxiosIU Indianapolis launches new partnership with Eli Lilly and CompanyFeb 1Arika HerronBy Arika Herronmore_vert
BloombergHow a Lucky Break Fueled Eli Lilly's $600 Billion Weight-Loss EmpireJan 25Madison MullerBy Madison Mullermore_vert
Financial TimesNovo Nordisk and Eli Lilly set to face new challenger in weight-loss raceJan 22more_vert
Reuters.comExclusive: US FDA finds new manufacturing lapses at Eli Lilly plantJan 19Marisa Taylor & Maggie FickBy Marisa Taylor & Maggie Fickmore_vert
STATReadout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, MerckJan 26Damian GardeBy Damian Gardemore_vert
PYMNTS.comCan Eli Lilly With LillyDirect Change the Delivery of Healthcare?Jan 22Karen L. WebsterBy Karen L. Webstermore_vert
Pharmaceutical TechnologyEli Lilly and Innovent's obesity drug mazdutide achieves positive Phase III resultsJan 11more_vert
Yahoo NewsLilly exec eyes more weight-loss drug launches this yearJan 16Patrick Wingrove & Divya ChowdhuryBy Patrick Wingrove & Divya Chowdhurymore_vert
FOX 59 IndianapolisNew lawsuit filed in federal court on new Eli Lilly and Company Alzheimer’s treatmentJan 3David GayBy David Gaymore_vert
CNNWeight loss drug Zepbound is now available, Eli Lilly saysDec 5Giri ViswanathanBy Giri Viswanathanmore_vert
Financial TimesEli Lilly's heavyweight status looks set to lastJan 16Roula KhalafBy Roula Khalafmore_vert
Verywell HealthLilly Is Bringing Its Weight Loss Drug Directly to ConsumersJan 10Fran KritzBy Fran Kritzmore_vert
Reuters.comEli Lilly extends tender offer deadline for Point Biopharma shares on low participationDec 5Mariam E Sunny & Shilpi MajumdarBy Mariam E Sunny & Shilpi Majumdarmore_vert
Barron'sEli Lilly's Mounjaro Outperforms Novo Nordisk's Ozempic: New StudyNov 28Josh Nathan-kazisBy Josh Nathan-kazismore_vert
Fierce BiotechLilly to build new pearly Gate(way) in sunny San Diego as third accelerator site selectedNov 28Max BayerBy Max Bayermore_vert
NBC NewsPharmaceutical giant Eli Lilly launches new website to expand patient access to key medicinesJan 4more_vert
The New York TimesF.D.A. Approves New Obesity Drug That Will Compete With WegovyNov 10Gina KolataBy Gina Kolatamore_vert
PR NewswireLilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development ActivityNov 2more_vert
UPI NewsEli Lilly names new head of diabetes and obesity division in leadership shakeupOct 4, 2023Doug CunninghamBy Doug Cunninghammore_vert
Yahoo Finance UKTrending tickers: Next | JD Sports | Tesla | Eli LillyJan 4Pedro GoncalvesBy Pedro Goncalvesmore_vert
Reuters.comEli Lilly extends tender offer to buy Point Biopharma after low participationNov 17Sriparna Roy & Shinjini GanguliBy Sriparna Roy & Shinjini Gangulimore_vert
CNNBlockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli LillyNov 2Samantha DelouyaBy Samantha Delouyamore_vert
MedCity NewsEli Lilly Plans New $2.5B Manufacturing Site in Germany for Injectable MedsNov 19Frank VinluanBy Frank Vinluanmore_vert
NOLA.comHow pharmaceutical giant Eli Lilly Co. left its mark on the New Orleans skylineSep 13, 2023more_vert
The Motley Fool3 of Eli Lilly's Top Drugs Grew by Over 40% in Q2. Trulicity Wasn't One of Them.Aug 17, 2023David JagielskiBy David Jagielskimore_vert
Fierce BiotechNektar CEO slams Lilly's 'egregious error,' laments lost timeAug 8, 2023Gabrielle MassonBy Gabrielle Massonmore_vert
OrrickEli Lilly to Acquire Versanis Bio in up to $1.925 Billion Deal With Potential Implications for Treating ObesityJul 20, 2023more_vert
Financial TimesEli Lilly drug shown to slow Alzheimer's progressionJul 17, 2023Clive CooksonBy Clive Cooksonmore_vert
Yahoo FinanceMissed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.Mar 9David JagielskiBy David Jagielskimore_vert
FOX 59 IndianapolisProgress is being made on new Eli Lilly and Company manufacturing facilitiesOct 28Hannah FollmanBy Hannah Follmanmore_vert
PR NewswireLilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand TherapiesOct 3, 2023more_vert